Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: A systematic review

Rheumatology

Volumn 50, Issue 9, 2011, Pages 1700-1711

  Brunasso, Alexandra M G ^a,b   Puntoni, Matteo ^b   Gulia, Andrea ^c   Massone, Cesare ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b GALLIERA HOSPITAL   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Adalimumab; Ankylosing spondylitis; Etanercept; Hepatitis C; Inflammatory bowel disease; Infliximab; Psoriasis; Rheumatoid arthritis; Safety; Vasculitis

Indexed keywords

ADALIMUMAB; AMINOTRANSFERASE; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; TUMOR NECROSIS FACTOR INHIBITOR;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CROHN DISEASE; DISEASE SEVERITY; DRUG SAFETY; HEPATITIS C; HUMAN; INFLAMMATORY DISEASE; LIVER DISEASE; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS; ARTHRITIS, RHEUMATOID; CROHN DISEASE; HEPATITIS C, CHRONIC; HUMANS; PSORIASIS; TRANSAMINASES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR DISEASES; VIRAL LOAD;

EID: 80051947010     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker190     Document Type: Article

References (73)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5: 558-67.
2. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007;13:2436-41.
3. Armstrong GL, Wasley A, Simard EP et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14.
4. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004;63:ii18-24.
5. Huerta C, Rivero E, Rodríguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007;143:1559-65.
6. Lawrence RC, Hochberg MC, Kelsey JL et al. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol 1989;16: 427-41.
7. Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis 2010;16:925-32.
8. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000;43:1431-42.
9. Ketikoglou I, Karatapanis S, Elefsiniotis I et al. Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. Eur J Dermatol 2005;15: 107-9.
10. Kartal ED, Colak H, Ozgunes I et al. Exacerbation of psoriasis due to peginterferon alpha-2b plus ribavirin treatment of chronic active hepatitis C. Chemotherapy 2005;5:167-9.
11. Citro V, Fristachi R, Tarantino G. Extensive psoriasis induced by pegylated interferon: a case report. J Med Case Reports 2007;17:86.
12. Yurci A, Guven K, Torun E et al. Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol 2007;19:811-5.
13. Galeazzi M, Bellisai F, Manganelli S et al. Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients. Autoimmun Rev 2006;5:493-8.
14. United States FDA. Safety alerts for drugs, biologics medical devices, and dietary supplements. Remicade (inFiximab). Washington DC: FDA, 2004. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm107702.pdf (29 June 2010, date last accessed).
15. United States FDA. Safety alerts for drugs, biologics medical devices, and dietary supplements. Enbrel (etanercept). Washington DC: FDA, 2004. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2003/103795-S5109-ENBREL.pdf. (29 June 2010, date last accessed).
16. United States FDA. Safety alerts for drugs, biologics medical devices, and dietary supplements. Humira (adalimumab). Washington DC: FDA, 2004. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2008/125057s110-SumR.pdf (29 June 2010, date last accessed).
17. United States FDA. Safety alerts for drugs, biologics medical devices, and dietary supplements. Golimumab (Simponi). Washington DC: FDA, 2008. http://www.drugs.com/newdrugs/simponi-golimumab-receives-fdaapproval-first-once-monthly-anti-tnf-rheumatoid-arthritispsoriatic-1329.html (18 January 2011, date last accessed).
18. United States FDA. Safety alerts for drugs, biologics medical devices, and dietary supplements. Certolizumab (Cimzia). http://www.medpagetoday.com/Geriatrics/Arthritis/14210. Washington DC: FDA, 2009.
19. United States FDA. Safety alerts for drugs, biologics medical devices, and dietary supplements. Remicade (inFiximab). Washington DC: FDA, 2004. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm166901.htm (29 June 2010, date last accessed).
20. Mancini S, Amorotti E, Vecchio S et al. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med 2010;5:193-200.
21. Linardaki G, Katsarou O, Ioannidou P et al. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 2007;34:1353-5.
22. Pritchard C. Etanercept and hepatitis C. J Clin Rheumatol 1999;5:179.
23. Peterson JR, Hsu FC, Simkin PA et al. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003;62: 1078-82.
24. Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004;51:800-4.
25. Oniankitan O, Duvoux C, Challine D et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004;31:107-9.
26. Niewold TB, Gibofsky A. Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C. Arthritis Rheum 2006; 54:2335-7.
27. Bellisai F, Giannitti C, Donvito A et al. Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. Clin Rheumatol 2007;26:1127-9.
28. Vauloup C, Krzysiek R, Greangeot-Keros L et al. Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities. Eur Cytokine Netw 2006;17:290-3.
29. Roux CH, Brocq O, Breuil V et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology 2006;45:1294-7.
30. Cavazzana I, Ceribelli A, Cattaneo R et al. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev 2008;8:104-6.
31. Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008;35: 421-4.
32. Ferri C, Ferraccioli G, Ferrari D et al. GISEA Group. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008;35:1944-9.
33. Kaur PP, Chan VC, Berney SN. Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports. Clin Rheumatol 2008;27:1069-71.
34. Li S, Kaur PP, Chan V et al. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol 2009;28:787-91.
35. Khanna MA, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatolog Treat 2003;14:229-32.
36. Aslanidis S, Vassiliadis T, Pyrpasopoulou A et al. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 2007;26:261-4.
37. Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004;51:580-4.
38. Cecchi R, Bartoli L. Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept). Dermatol Online J 2006;12:4.
39. Piccolo D, Di Cesare A, Fargnoli MC et al. Effective control of psoriasis by etanercept in a patient with HCV-related diseases. Eur J Dermatol 2008;18:459-60.
40. Alcaide AJ, Barrera MV, Habicheyn S et al. Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection. J Eur Acad Dermatol Venereol 2008;22:1514-16.
41. Prignano F, Zanieri F, Milani S et al. Switch from etanercept to efalizumab in a psoriatic patient with HCV infection: a case report. Dermatol Ther 2009;22:386-90.
42. Behnam SE, Hindiyeh R, Fife DJ et al. Etanercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection. Clin Exp Dermatol 2010;35:397-8.
43. Rokhsar C, Rabhan N, Cohen SR. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol 2006;54:361-2.
44. Collazo MH, Gonzàlez JR, Torres EA. Etanercept therapy for psoriasis in a patient with concomitant hepatitis C and liver transplant. P R Health Sci J 2008;27:346-7.
45. De Simone C, Paradisi A, Capizzi R et al. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 2006;54:1102-4.
46. Campbell S, Ghosh S. Infliximab treatment for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001;13:191-2.
47. Biancone L, Del Vecchio Blanco G et al. Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection. Gastroenterology 2002; 122:593-4.
48. Holtmann MH, Galle PR, Neurath MF. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol 2003;98:504-5.
49. Alderson JW, Van Dinter TG Jr, Opatowsky MJ et al. Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature. Med Gen Med 2005;7:7.
50. Abdelmalek MF, Liu C, Valentine JF. Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease. Am J Gastroenterol 2007;102:1333-4.
51. Bartolucci P, Ramanoelina J, Cohen P et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology 2002;41:1126-32.
52. Chandesris MO, Gayet S, Schleinitz N et al. Infliximab in the treatment of refractory vasculitis secondary to hepatitis C-associated mixed cryoglobulinaemia. Rheumatology 2004;43:532-3.
53. Zein NN. Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin treatment-naive patients with chronic hepatitis C virus infection: a Phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315-22.
54. Marotte H, Fontanges E, Bailly F et al. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology 2007;46:97-99.
55. Brunasso AM, Delfino C, Gulia A et al. Safety of anti-tumor necrosis factor agents in patients with chronic hepatitis C infection. Adv Psor Inflamm Skin Dis 2010;2:17-24.
56. Ventura F, Gomes J, Duarte MD et al. Efficacy and safety of etanercept in patients with psoriasis and hepatitis C. Eur J Dermatol 2010;20:808-9.
57. Paradisi A, Caldarola G, Capizzi R et al. Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: preliminary data. J Am Acad Dermatol 2010;62:1067-9.
58. Haennig A, Bonnet D, Thebault S et al. Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab. Gastroenterol Clin Biol 2010;34:e7-8.
59. Tsai SL, Liaw YF, Chen MH et al. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997;25: 449-58.
60. Berg L, Lampa J, Rogberg S et al. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNF-alpha receptors. Ann Rheum Dis 2001;60:133-9.
61. Arase Y, Ikeda K, Chayama K et al. Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C. J Gastroenterol 2000;35:221-5.
62. Gonzalez-Amaro R, Garcia-Monzon C, Garcia-Buey L et al. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med 1994;179:841-8.
63. Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 2006;26:55-62.
64. Amital H, Arnson Y, Chodick G et al. Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate. Rheumatology 2009; 48:1107-10.
65. Kluger N, Girard C, Guillot B et al. Efficiency and safety of etanercept after acute hepatitis induced by infliximab for psoriasis. Acta Derm Venereol 2009;89:332-4.
66. Thiéen G, Morelet A, Heurgué A et al. InFiximab-induced hepatitis: absence of cross-toxicity with etanercept. Joint Bone Spine 2008;75:737-9.
67. García Aparicio AM, Rey JR, Sanz AH et al. Successful treatment with etanercept in a patient with hepatotoxicity closely related to inFiximab. Clin Rheumatol 2007;26: 811-13.
68. Carlsen KM, Riis L, Madsen OR. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol 2009;28:1001-3.
69. Furst DE, Keystone EC, Kirkham B et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases 2008. Ann Rheum Dis 2008;67:iii2-25.
70. Ghany MG, Strader DB, Thomas DL et al. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
71. Pontisso P, Bellati G, Brunetto M et al. Hepatitis C virus RNA profiles in chronically infected individuals: do they relate to disease activity? Hepatology 1999;29: 585-9.
72. Menter A, Gottlieb A, Feldman SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50.
73. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161:987-1019.